by What is the Alzheimers Disease Diagnostics Market Size?
The global Alzheimer’s Disease Diagnostics Market size was calculated at USD 9.40 billion in 2025 and is projected to grow from USD 10.42 billion in 2026 to estimated USD 26.21 billion by 2035, registering a CAGR of 10.80% during the forecast period from 2026 to 2035.
Alzheimers Disease Diagnostics Market Key Takeaways
- North America dominated the global Alzheimer’s disease diagnostics market, accounting for a 42% share in 2025.
- Asia-Pacific is expected to grow at the fastest CAGR of 14% during the forecast period.
- By diagnostic type, the brain imaging segment held a dominant position in the market, accounting for 38% of the market share in 2025.
- By diagnostic type, the biomarker testing segment is expected to grow at the fastest CAGR 16% between 2026 and 2035.
- By technology, the imaging technologies segment accounted for a considerable revenue share of 45% in the market in 2025.
- By technology, the AI and digital diagnostics segment is expected to grow at the highest CAGR 18% between 2026 and 2035.
- By end-use, the hospitals segment led the global market, accounting for 45% of the market in 2025.
- By end-use, the diagnostic laboratories segment is expected to grow at the fastest CAGR 13% between 2026 and 2035.
- By application, the early-stage diagnosis segment accounted for a considerable revenue share of 40% in the market in 2025.
- By application, the mild cognitive impairment detection segment is expected to grow at a 10% CAGR between 2026 and 2035.
- By age group, the 65-80 years segment accounted for a considerable revenue share of 48% in the market in 2025.
- By age group, the above 80 years segment is expected to grow at the fastest CAGR of 12.5% between 2026 and 2035.
Key AI Integration in the Alzheimers Disease Diagnostics Market
The integration of Artificial Intelligence is transforming the Alzheimer’s disease diagnostics market by enabling faster, more accurate, and highly efficient disease detection and assessment. Advanced AI algorithms are increasingly being used to identify subtle early-stage brain changes associated with Alzheimer’s disease through imaging technologies such as MRI and PET scans.
Machine learning models can analyze vast amounts of patient data, including imaging results, biomarker tests, cognitive assessments, and genetic information, helping healthcare professionals improve diagnostic accuracy and support earlier intervention. These AI-driven technologies are enhancing clinical decision-making, streamlining diagnostic workflows, and improving patient outcomes in Alzheimer’s disease management.
Alzheimers Disease Diagnostics Market Regional Insights
North America Alzheimer’s Disease Diagnostics Market Size and Growth 2026 to 2035
The North America Alzheimer’s disease diagnostics market size was valued at USD 3.95 billion in 2025 and is projected to reach approximately USD 10.42 billion by 2035, expanding at a CAGR of 10.20% during the forecast period from 2026 to 2035.
Which Factors Drive the Alzheimer’s Disease Diagnostics Market in North America?
North America dominated the global market with a share of 42% in 2025, because cutting-edge brain imaging techniques were adopted by many health care facilities, and there are PET and MRI scanners available. This is because it spreads its expenses for healthcare, its reimbursement policies are well-established, and they adopt new diagnostic solutions quickly into its clinical practice. With the ageing population, it is even more essential to develop diagnostic tests as soon as possible and as accurately as possible, and as a result, the frequency of Alzheimer’s disease is also rising.
U.S. Alzheimer’s Disease Diagnostics Market Size and Growth 2026 to 2035
The United States Alzheimer’s disease diagnostics market size was valued at USD 2.96 billion in 2025 and is expected to reach approximately USD 7.87 billion by 2035, expanding at a CAGR of 10.28% during the forecast period from 2026 to 2035.
U.S. Market Trends
The U.S. represents a large market in North America, with its well-established healthcare ecosystem and prolific research activities and innovations focused on the nervous system. The widespread use of PET imaging systems, MRI systems, and newly developed blood-based biomarker testing is contributing to a better detection rate of disease. Furthermore, there are efforts to invest in the diagnosis and therapeutic studies of Alzheimer’s at the government and private levels.
Alzheimers Disease Diagnostics Market Market Dynamics
Drivers
Growing Awareness and Education
The increasing awareness of Alzheimer’s disease and other cognitive disorders is playing a major role in driving the growth of the Alzheimer’s disease diagnostics market. Governments, healthcare institutions, and advocacy organizations are actively conducting educational campaigns to raise awareness about Alzheimer’s symptoms, risk factors, and the importance of early diagnosis and timely intervention.
In addition, significant advancements in healthcare professional training are improving the accuracy of disease diagnosis and patient management. Enhanced expertise in biomarker testing, neuroimaging technologies, and cognitive assessment tools is enabling healthcare providers to deliver more precise and efficient diagnostic outcomes, further supporting market expansion.
Alzheimers Disease Diagnostics Market Segmental Insights
End-use Insights
The Hospitals Segment Held the Largest Market Share of 45% in 2025
The hospitals segment dominated the global Alzheimer’s Disease Diagnostics Market with a market share of 45% in 2025, driven by the increasing number of patients undergoing neurological evaluations and the availability of advanced imaging and diagnostic technologies. Hospitals serve as key centers for Alzheimer’s diagnosis due to their integrated healthcare infrastructure, specialized neurology departments, and access to multidisciplinary care teams.
The rising demand for comprehensive diagnostic services, including neuroimaging, biomarker testing, and cognitive assessment procedures, is further contributing to the growth of the hospital segment. In addition, hospitals are increasingly adopting advanced diagnostic tools and AI-powered technologies to improve the accuracy and efficiency of Alzheimer’s disease detection and patient management.
Alzheimers Disease Diagnostics Market Companies
- Labcorp
Labcorp is a leading global life sciences and diagnostics company providing advanced laboratory testing and healthcare solutions. The company plays a significant role in biomarker testing and neurological disease diagnostics, including Alzheimer’s disease detection. - Canon Medical Systems
Canon Medical Systems specializes in advanced medical imaging technologies such as MRI, CT, and ultrasound systems. The company supports Alzheimer’s disease diagnostics through high-precision neuroimaging solutions and AI-enabled healthcare technologies. - Philips Healthcare
Philips Healthcare offers innovative diagnostic imaging, patient monitoring, and healthcare informatics solutions. The company focuses on AI-powered imaging and neurological diagnostic technologies to improve early detection of Alzheimer’s disease. - Bio-Rad Laboratories
Bio-Rad Laboratories develops diagnostic products and life science research technologies used in clinical testing and disease research. The company contributes to Alzheimer’s diagnostics through biomarker testing and advanced laboratory solutions. - Quanterix
Quanterix is known for its ultra-sensitive biomarker detection technologies used in neurological disease research and diagnostics. The company’s advanced testing platforms support early-stage detection and monitoring of Alzheimer’s disease progression. - Abbott Laboratories
Abbott Laboratories is a global healthcare company offering diagnostics, medical devices, nutrition, and pharmaceutical products. The company develops innovative diagnostic solutions that support neurological disease testing and patient care. - Sysmex Corporation
Sysmex Corporation specializes in diagnostic laboratory equipment and healthcare testing technologies. The company focuses on improving diagnostic efficiency and precision through advanced clinical testing systems and automation solutions. - PerkinElmer
PerkinElmer provides analytical instruments, diagnostic solutions, and life science technologies for healthcare and research applications. The company supports neurological disease research and biomarker analysis for early Alzheimer’s detection.
Check this report to: ATM Managed Services Market
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview: https://www.precedenceresearch.com/sample/8427
You can place an order or ask any questions. Please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344
